This content is machine translated Non-resectable melanoma New triple therapy improves progression-free survival Both protein kinase inhibitors and ipilimumab/nivolumab combined have better efficacy than their respective monotherapies in patients with non-resectable melanoma. This has been known for some time. An interesting new approach…
View Post 4 min This content is machine translated 28th German Skin Cancer Congress 2018, Stuttgart Update on immunotherapy of malignant melanoma Combination immunotherapy, adjuvant immune checkpoint blockade, and long-term survival after PD-1 inhibitor therapy were the topics of two satellite symposia at the German Skin Cancer Congress.
View Post 6 min This content is machine translated ESMO 2017 in Madrid Blocking the “escape route” for the tumor Upsets in first-line therapy of non-small cell EGFR-mutated lung cancer are imminent. With the FLAURA trial, osimertinib is confidently presenting itself for the first time as a treatment option for…
View Post 2 min This content is machine translated Non-small cell lung cancer Swiss approval of nivolumab As of November 30, 2015, nivolumab (Opdivo®) has been approved for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy (regardless of histological subtype). This takes into…
View Post 7 min This content is machine translated From RAPID to RATHL Current treatment options for Hodgkin’s lymphoma The option of sequential PET computed tomography (PET) scans opens up new possibilities in the treatment of Hodgkin lymphoma. Current standard therapy in low-risk patients consists of two cycles of…
View Post 2 min This content is machine translated New study on combined immunotherapy in melanoma Combination of nivolumab and ipilimumab is superior to monotherapy Melanomas account for less than 5% of all skin cancers, but they claim the most lives. How to optimize the therapy? The CheckMate-069 trial, published in the New England Journal…
View Post 4 min This content is machine translated News from dermatooncology Melanoma with or without BRAF mutation – new therapies in the pipeline Data from two phase III trials (both from the research group led by Caroline Robert, MD, Institut Gustave Roussy in Villejuif, Paris) published earlier this year highlight the rapid development…
View Post 3 min This content is machine translated News from the ASH Congress on Nivolumab High response rates even in pretreated Hodgkin’s lymphomas Preclinical studies show that Sternberg-Reed cells, characteristic of classical Hodgkin lymphoma, use the PD-1 pathway to evade immunodetection. Therefore, immune checkpoint inhibitors such as nivolumab, which binds to the PD-1…
View Post 4 min This content is machine translated Immuno-Oncology New pathways for improved cancer treatment? Long-term survival of patients with advanced-stage carcinoma is still an area where research is far from successful. In the field of melanoma, the approval of ipilimumab in 2011 has made…
View Post 3 min This content is machine translated News on melanoma therapy at ASCO 2014 How do immunotherapies work in combination and in the adjuvant setting? In the course of this year’s ASCO congress in Chicago at the beginning of June, new results of the phase Ib study on the combination of PD1 and CTLA4 inhibition…
